COVID-19 in multiple sclerosis: The Dutch experience
COVID-19 in multiple sclerosis: The Dutch experience
复制标题
DOI：
10.1177/1352458520942198
复制
发表时间：
2020-07-14
影响因子：
5.8
通讯作者：
Mostert, Jop P.
中科院分区：
文献类型：
--
作者：
Loonstra, Floor C.;Hoitsma, Elske;Mostert, Jop P.
在这里，我们提供了荷兰多发性硬化症(MS)患者在2020年2月27日至6月9日期间报告的所有新冠肺炎病例的广泛概述，这些病例是由荷兰神经学会多发性硬化症工作组收集的。共有86名多发性硬化症患者被报告，其中43人新冠肺炎检测呈阳性。在43名检测呈阳性的患者中，有22名患者住院治疗。据报道，有3人入院重症监护病房(ICU)，4人死亡。我们的研究结果显示，荷兰多发性硬化症患者在疾病修改治疗的使用和新冠肺炎病程方面没有明显差异。此外，没有观察到淋巴细胞计数低与严重疾病之间的明显联系。
Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis (MS) patients in the Netherlands between 27 February and 9 June 2020, gathered by the Dutch MS Taskforce of the Netherlands Society of Neurology. A total of 86 MS patients were reported, 43 of whom tested positive for COVID-19. Of 43 patients who tested positive, 22 patients were hospitalized. Three intensive care unit (ICU) admissions and four deaths were reported. Our findings show no apparent difference in disease-modifying treatment (DMT) use and COVID-19 disease course in Dutch MS patients. In addition, a clear link between low lymphocyte count and severe disease was not observed.